An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer

Mei Ying Liao, Jun Kai Lai, Mark Yen Ping Kuo, Ruei Min Lu, Cheng Wei Lin, Ping Chang Cheng, Kang Hao Liang, Han Chung Wu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Epithelial cell adhesion molecule (EpCAM) is known to be overexpressed in epithelial cancers associated with enhanced malignant potential, particularly colorectal carcinoma (CRC) and head and neck squamous cell carcinoma (HNSCC). However, it is unknown whether progression of malignance can be directly inhibited by targeting EpCAM. Here, we have generated five novel monoclonal antibodies (mAbs) against EpCAM. One of these anti-EpCAM mAbs, EpAb2-6, was found to induce cancer cell apoptosis in vitro, inhibit tumor growth, and prolong the overall survival of both a pancreatic cancer metastatic mouse model and mice with human colon carcinoma xenografts. EpAb2-6 also increases the therapeutic efficacy of irinotecan, fluorouracil, and leucovorin (IFL) therapy in a colon cancer animal model and gemcitabine therapy in a pancreatic cancer animal model. Furthermore, EpAb2-6, which binds to positions Y95 and D96 of the EGF-II/TY domain of EpCAM, inhibits production of EpICD, thereby decreasing its translocation and subsequent signal activation. Collectively, our results indicate that the novel anti-EpCAM mAb can potentially be used for cancer-targeted therapy.

Original languageEnglish
Pages (from-to)24947-24968
Number of pages22
JournalOncotarget
Volume6
Issue number28
DOIs
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Colonic Neoplasms
Antibodies
irinotecan
gemcitabine
Pancreatic Neoplasms
Neoplasms
Animal Models
Monoclonal Antibodies
Leucovorin
Therapeutics
Epidermal Growth Factor
Heterografts
Fluorouracil
Epithelial Cell Adhesion Molecule
Colorectal Neoplasms
Colon
Apoptosis
Carcinoma
Survival
Growth

Keywords

  • Cancer therapy
  • Colorectal carcinoma
  • EpCAM
  • Targeting imaging
  • Therapeutic antibody

ASJC Scopus subject areas

  • Oncology

Cite this

Liao, M. Y., Lai, J. K., Kuo, M. Y. P., Lu, R. M., Lin, C. W., Cheng, P. C., ... Wu, H. C. (2015). An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget, 6(28), 24947-24968. https://doi.org/10.18632/oncotarget.4453

An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. / Liao, Mei Ying; Lai, Jun Kai; Kuo, Mark Yen Ping; Lu, Ruei Min; Lin, Cheng Wei; Cheng, Ping Chang; Liang, Kang Hao; Wu, Han Chung.

In: Oncotarget, Vol. 6, No. 28, 2015, p. 24947-24968.

Research output: Contribution to journalArticle

Liao, MY, Lai, JK, Kuo, MYP, Lu, RM, Lin, CW, Cheng, PC, Liang, KH & Wu, HC 2015, 'An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer', Oncotarget, vol. 6, no. 28, pp. 24947-24968. https://doi.org/10.18632/oncotarget.4453
Liao, Mei Ying ; Lai, Jun Kai ; Kuo, Mark Yen Ping ; Lu, Ruei Min ; Lin, Cheng Wei ; Cheng, Ping Chang ; Liang, Kang Hao ; Wu, Han Chung. / An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. In: Oncotarget. 2015 ; Vol. 6, No. 28. pp. 24947-24968.
@article{0461901c3ff34ad3bbcf81e36079ab2b,
title = "An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer",
abstract = "Epithelial cell adhesion molecule (EpCAM) is known to be overexpressed in epithelial cancers associated with enhanced malignant potential, particularly colorectal carcinoma (CRC) and head and neck squamous cell carcinoma (HNSCC). However, it is unknown whether progression of malignance can be directly inhibited by targeting EpCAM. Here, we have generated five novel monoclonal antibodies (mAbs) against EpCAM. One of these anti-EpCAM mAbs, EpAb2-6, was found to induce cancer cell apoptosis in vitro, inhibit tumor growth, and prolong the overall survival of both a pancreatic cancer metastatic mouse model and mice with human colon carcinoma xenografts. EpAb2-6 also increases the therapeutic efficacy of irinotecan, fluorouracil, and leucovorin (IFL) therapy in a colon cancer animal model and gemcitabine therapy in a pancreatic cancer animal model. Furthermore, EpAb2-6, which binds to positions Y95 and D96 of the EGF-II/TY domain of EpCAM, inhibits production of EpICD, thereby decreasing its translocation and subsequent signal activation. Collectively, our results indicate that the novel anti-EpCAM mAb can potentially be used for cancer-targeted therapy.",
keywords = "Cancer therapy, Colorectal carcinoma, EpCAM, Targeting imaging, Therapeutic antibody",
author = "Liao, {Mei Ying} and Lai, {Jun Kai} and Kuo, {Mark Yen Ping} and Lu, {Ruei Min} and Lin, {Cheng Wei} and Cheng, {Ping Chang} and Liang, {Kang Hao} and Wu, {Han Chung}",
year = "2015",
doi = "10.18632/oncotarget.4453",
language = "English",
volume = "6",
pages = "24947--24968",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "28",

}

TY - JOUR

T1 - An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer

AU - Liao, Mei Ying

AU - Lai, Jun Kai

AU - Kuo, Mark Yen Ping

AU - Lu, Ruei Min

AU - Lin, Cheng Wei

AU - Cheng, Ping Chang

AU - Liang, Kang Hao

AU - Wu, Han Chung

PY - 2015

Y1 - 2015

N2 - Epithelial cell adhesion molecule (EpCAM) is known to be overexpressed in epithelial cancers associated with enhanced malignant potential, particularly colorectal carcinoma (CRC) and head and neck squamous cell carcinoma (HNSCC). However, it is unknown whether progression of malignance can be directly inhibited by targeting EpCAM. Here, we have generated five novel monoclonal antibodies (mAbs) against EpCAM. One of these anti-EpCAM mAbs, EpAb2-6, was found to induce cancer cell apoptosis in vitro, inhibit tumor growth, and prolong the overall survival of both a pancreatic cancer metastatic mouse model and mice with human colon carcinoma xenografts. EpAb2-6 also increases the therapeutic efficacy of irinotecan, fluorouracil, and leucovorin (IFL) therapy in a colon cancer animal model and gemcitabine therapy in a pancreatic cancer animal model. Furthermore, EpAb2-6, which binds to positions Y95 and D96 of the EGF-II/TY domain of EpCAM, inhibits production of EpICD, thereby decreasing its translocation and subsequent signal activation. Collectively, our results indicate that the novel anti-EpCAM mAb can potentially be used for cancer-targeted therapy.

AB - Epithelial cell adhesion molecule (EpCAM) is known to be overexpressed in epithelial cancers associated with enhanced malignant potential, particularly colorectal carcinoma (CRC) and head and neck squamous cell carcinoma (HNSCC). However, it is unknown whether progression of malignance can be directly inhibited by targeting EpCAM. Here, we have generated five novel monoclonal antibodies (mAbs) against EpCAM. One of these anti-EpCAM mAbs, EpAb2-6, was found to induce cancer cell apoptosis in vitro, inhibit tumor growth, and prolong the overall survival of both a pancreatic cancer metastatic mouse model and mice with human colon carcinoma xenografts. EpAb2-6 also increases the therapeutic efficacy of irinotecan, fluorouracil, and leucovorin (IFL) therapy in a colon cancer animal model and gemcitabine therapy in a pancreatic cancer animal model. Furthermore, EpAb2-6, which binds to positions Y95 and D96 of the EGF-II/TY domain of EpCAM, inhibits production of EpICD, thereby decreasing its translocation and subsequent signal activation. Collectively, our results indicate that the novel anti-EpCAM mAb can potentially be used for cancer-targeted therapy.

KW - Cancer therapy

KW - Colorectal carcinoma

KW - EpCAM

KW - Targeting imaging

KW - Therapeutic antibody

UR - http://www.scopus.com/inward/record.url?scp=84944463696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944463696&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4453

DO - 10.18632/oncotarget.4453

M3 - Article

VL - 6

SP - 24947

EP - 24968

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 28

ER -